This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Biological Therapy in Treating Patients With Metastatic Melanoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Fred Hutchinson Cancer Research Center Identifier:
First received: September 6, 2002
Last updated: May 5, 2010
Last verified: May 2010

RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's white blood cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

Condition Intervention Phase
Melanoma (Skin) Biological: aldesleukin Biological: therapeutic tumor infiltrating lymphocytes Phase 1

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen Specific T Cell Clones Targeting Cancer Testis Antigens for Patients With Metastatic Melanoma

Resource links provided by NLM:

Further study details as provided by Fred Hutchinson Cancer Research Center:

Study Start Date: October 2002
Study Completion Date: June 2005
Detailed Description:



  • Determine the safety and toxicity of cellular adoptive immunotherapy comprising autologous CD8+ cytotoxic T-lymphocyte clones targeting cancer-testis antigens in patients with metastatic melanoma.
  • Determine the duration of in vivo persistence of this therapy in these patients.


  • Evaluate the antitumor effects of this therapy in these patients.

OUTLINE: Patients undergo leukapheresis to obtain peripheral blood mononuclear cells and then CD8+ cytotoxic T-lymphocyte (CTL) clones are generated ex vivo. Patients receive cellular adoptive immunotherapy comprising autologous CD8+ CTL clones targeting cancer testis antigens IV over 30 minutes on day 1. Patients also receive interleukin-2 subcutaneously every 12 hours on days 1-14 of courses 2-4. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a clinical response after completion of the fourth course are eligible to receive additional T-cell infusions.

Patients are followed for 9 months.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 3 years.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed metastatic melanoma

    • Stage IV disease
  • HLA-A1, -A2, and -A3 positive
  • MAGE-1 or -3 positive by histology
  • Bidimensionally measurable disease by palpation on clinical examination, x-ray, or CT scan
  • No CNS metastases



  • 18 to 75

Performance status

  • Karnofsky 80-100%

Life expectancy

  • More than 6 months


  • Not specified


  • Bilirubin ≤ 1.6 mg/dL
  • SGOT ≤ 3 times upper limit of normal
  • PT ≤ 1.5 times control


  • Creatinine ≤ 2.0 mg/dL
  • Calcium ≤ 12 mg/dL


  • No congestive heart failure
  • No clinically significant hypotension
  • No symptoms of coronary artery disease
  • No cardiac arrhythmias on electrocardiogram requiring drug therapy
  • Patients with prior cardiovascular disease or the presence of any of the above abnormalities undergo a cardiac evaluation, which may include a stress test and/or echocardiogram


  • No clinically significant pulmonary dysfunction by medical history or physical examination
  • FEV_1 ≥ 60% of normal
  • DLCO ≥ 55% (corrected for hemoglobin)


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No retinitis or choroiditis
  • No active infections or oral temperature greater than 38.2 degrees Celsius within the past 72 hours
  • No systemic infection requiring chronic maintenance or suppressive therapy


Biologic therapy

  • No other concurrent immunotherapy (e.g., other interleukins, interferons, melanoma vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating lymphocytes or lymphokine-activated killer cell therapy)


  • At least 3 weeks since prior standard or experimental chemotherapy
  • 1-2 courses of prior cytoreductive chemotherapy for bulky disease allowed

Endocrine therapy

  • No concurrent systemic steroids (except for toxicity management)


  • At least 3 weeks since prior radiotherapy


  • Not specified


  • At least 3 weeks since prior immunosuppressive therapy
  • No concurrent pentoxifylline
  • No other concurrent investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00045149

United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109-1024
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Study Chair: Cassian Yee, MD Fred Hutchinson Cancer Research Center
  More Information Identifier: NCT00045149     History of Changes
Obsolete Identifiers: NCT00029432
Other Study ID Numbers: 1588.00
CDR0000256451 ( Registry Identifier: PDQ )
Study First Received: September 6, 2002
Last Updated: May 5, 2010

Keywords provided by Fred Hutchinson Cancer Research Center:
recurrent melanoma
stage IV melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents processed this record on September 21, 2017